To compare the efficacy and safety of mometasone furoate dry powder inhaler (DPI) administered once daily in the evening with fluticasone propionate metered-dose inhaler (MDI) administered twice daily.Methods:
An 8-week, randomized, open-label, parallel-group study compared mometasone furoate DPI, 400 μg every evening (1 puff daily), with fluticasone propionate MDI, two 125-μg puffs twice daily, in 167 adults and adolescents with moderate persistent asthma previously using fluticasone propionate. The primary efficacy variable was the change in forced expiratory volume in 1 second (FEV1) from baseline to the end point. Variables such as response to therapy and subject satisfaction with the inhaler devices were also analyzed.Results:
Improvement in FEV1 was noted at the week 2 visit with both treatments. This improvement was maintained at the 4- and 8-week visits and at the end point for both groups. The mean percent change in FEV1 from baseline to the end point was 4.58% with mometasone furoate DPI and 6.98% with fluticasone propionate MDI (P = .35). At the end point, physicians rated 62% of the mometasone furoate DPI group as “improved” or “much improved” compared with 47% of the fluticasone propionate MDI group (P = .007). A significantly greater proportion of subjects in the mometasone furoate DPI group “liked the inhaler a lot” vs subjects in the fluticasone propionate MDI group (46.8% vs 22.4%; P = .01). Both treatments were well tolerated.Conclusion:
Mometasone furoate DPI, 400 μg every evening, provided comparable efficacy as fluticasone propionate MDI, two 125-μg puffs twice daily, in subjects with moderate persistent asthma previously treated with fluticasone propionate.Conclusion:
Ann Allergy Asthma Immunol. 2004;93:49-55.